

Julie Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556911/publications.pdf>

Version: 2024-02-01

33
papers

1,178
citations

471509

17
h-index

501196

28
g-index

33
all docs

33
docs citations

33
times ranked

2139
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential and controversy of targeting STAT family members in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 41-56.	9.6	226
2	CD70: An emerging target in cancer immunotherapy. , 2015, 155, 1-10.		136
3	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , 2019, 11, 1597.	3.7	77
4	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. <i>Cancers</i> , 2019, 11, 458.	3.7	73
5	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 22666-22679.	1.8	62
6	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. <i>Journal of Immunology Research</i> , 2015, 2015, 1-16.	2.2	54
7	The CD70-CD27 axis in oncology: the new kids on the block. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 12.	8.6	53
8	APR-246 (PRIMA-1 MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , 2016, 375, 313-322.	7.2	51
9	<sc>CD</sc>70 and <sc>PD</sc>â€1 in anaplastic thyroid cancerâ€ Promising targets for immunotherapy. <i>Histopathology</i> , 2017, 71, 357-365.	2.9	47
10	Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 13462-13475.	1.8	45
11	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1 α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. <i>Cancers</i> , 2018, 10, 126.	3.7	43
12	Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 1474.	4.1	37
13	Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. <i>Oncimmunology</i> , 2018, 7, e1440167.	4.6	33
14	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 113-124.	3.8	26
15	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. <i>British Journal of Cancer</i> , 2020, 123, 752-761.	6.4	25
16	Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. <i>Cancers</i> , 2019, 11, 1611.	3.7	23
17	Deep sequencing of the <i>TP53</i> gene reveals a potential risk allele for nonâ€small cell lung cancer and supports the negative prognostic value of <i>TP53</i> variants. <i>Tumor Biology</i> , 2017, 39, 101042831769432.	1.8	22
18	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2183.	4.1	22

#	ARTICLE	IF	CITATIONS
19	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. <i>Cancers</i> , 2020, 12, 863.	3.7	18
20	A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting. <i>Cancers</i> , 2018, 10, 290.	3.7	17
21	<i>In vitro</i> study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , 2019, 13, 1196-1213.	4.6	17
22	Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1573-1583.	4.2	15
23	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2022, 128, 1004-1014.	4.1	12
24	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. <i>Journal of Cancer</i> , 2017, 8, 1441-1452.	2.5	11
25	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4182.	4.1	11
26	Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. <i>Oncotarget</i> , 2017, 8, 74058-74067.	1.8	9
27	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , 2019, 11, 1893.	3.7	7
28	MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. <i>Journal of Cancer</i> , 2017, 8, 2154-2162.	2.5	4
29	Abstract 958: Blocking CD70+ cancer associated fibroblasts: Are we paving the way towards immunotherapy in colorectal cancer. <i>Cancer Research</i> , 2017, 77, 958-958.	0.9	2
30	Abstract 3563: Unlocking the potential of CD70 as a therapeutic target in non-small cell lung cancer. , 2015, , .		0
31	Abstract 3507: APR-246 reactivates mutant p53 in non-small cell lung cancer cell lines and sensitizes cells for CDDP treatment under normoxic and hypoxic conditions. , 2015, , .		0
32	Abstract 4328: New perspectives on the use of polo-like kinase 1 as a prognostic biomarker in non-small cell lung cancer. , 2015, , .		0
33	Abstract 4981: Cisplatin and anti-CD70 therapy: Ideal partners in crime against NSCLC. , 2016, , .		0